NASDAQ:IFRX InflaRx (IFRX) Stock Price, News & Analysis $0.88 -0.01 (-0.58%) As of 09:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InflaRx Stock (NASDAQ:IFRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InflaRx alerts:Sign Up Key Stats Today's Range$0.86▼$0.8650-Day Range$0.73▼$1.8552-Week Range$0.71▼$2.82Volume9,387 shsAverage Volume305,804 shsMarket Capitalization$58.74 millionP/E RatioN/ADividend YieldN/APrice Target$6.60Consensus RatingBuy Company Overview InflaRx NV is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic antibodies targeting components of the innate immune system. The company’s lead program is vilobelimab (IFX-1), a monoclonal antibody that selectively inhibits the complement factor C5a, a potent driver of inflammation. InflaRx is advancing vilobelimab in multiple indications, including hidradenitis suppurativa, paroxysmal nocturnal hemoglobinuria and other rare and severe inflammatory diseases, with both ongoing and planned clinical trials. Founded in 2007 and headquartered in Jena, Germany, InflaRx maintains operational offices in the United States to support its North American development and regulatory activities. The company has established strategic collaborations for manufacturing and clinical research in Europe and North America, ensuring access to state-of-the-art facilities and patient populations. InflaRx completed its initial public offering on the NASDAQ stock exchange in 2019 to accelerate its pipeline advancement and expand global clinical programs. Under the leadership of Chief Executive Officer Jan Schmidt, InflaRx is led by a management team with extensive experience in immunology, drug development and regulatory affairs. The company’s board and scientific advisory group include industry veterans from biotechnology and pharmaceutical backgrounds who guide strategy and clinical program design. InflaRx remains committed to translating its complement-modulating platform into novel therapies that address unmet needs in inflammatory and autoimmune diseases worldwide.AI Generated. May Contain Errors. Read More InflaRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreIFRX MarketRank™: InflaRx scored higher than 55% of companies evaluated by MarketBeat, and ranked 497th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInflaRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInflaRx has only been the subject of 3 research reports in the past 90 days.Read more about InflaRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for InflaRx are expected to decrease in the coming year, from ($1.04) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InflaRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.21% of the float of InflaRx has been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.21% of the float of InflaRx has been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.65 News SentimentInflaRx has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for InflaRx this week, compared to 2 articles on an average week.Search Interest2 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InflaRx's insider trading history. Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Stock News HeadlinesInflaRx Announces Receipt of Nasdaq Deficiency Notice ... - MorningstarJuly 12 at 11:46 PM | morningstar.comMInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum ...July 12 at 11:46 PM | seekingalpha.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 14 at 2:00 AM | Porter & Company (Ad)InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 12 at 12:12 PM | finanznachrichten.deInflaRx N.V. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementJuly 11 at 4:44 PM | quiverquant.comQInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 11 at 4:15 PM | globenewswire.comInflaRx N.V. (IFRX) Latest Stock News & Headlines - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comInflaRx Appoints KPMG as New Auditor Following Shareholder ApprovalJune 27, 2025 | tipranks.comSee More Headlines IFRX Stock Analysis - Frequently Asked Questions How have IFRX shares performed this year? InflaRx's stock was trading at $2.47 at the start of the year. Since then, IFRX stock has decreased by 64.4% and is now trading at $0.8801. How were InflaRx's earnings last quarter? InflaRx N.V. (NASDAQ:IFRX) issued its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The business earned $0.03 million during the quarter, compared to analyst estimates of $0.03 million. When did InflaRx IPO? InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA). Company Calendar Last Earnings5/07/2025Today7/14/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IFRX CIK1708688 Webwww.inflarx.de Phone493641508180Fax49-36-4150-8181Employees60Year FoundedN/APrice Target and Rating Average Price Target for InflaRx$6.60 High Price Target$10.00 Low Price Target$2.00 Potential Upside/Downside+654.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.85 million Net MarginsN/A Pretax Margin-33,646.85% Return on Equity-64.17% Return on Assets-53.39% Debt Debt-to-Equity RatioN/A Current Ratio5.28 Quick Ratio4.86 Sales & Book Value Annual Sales$180 thousand Price / Sales326.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book0.77Miscellaneous Outstanding Shares67,130,000Free Float56,190,000Market Cap$58.74 million OptionableOptionable Beta1.29 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:IFRX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.